Terms: = Breast cancer AND MYCL, LMYC, 4610, MYCL1, ENSG00000116990 AND Prognosis
10 results:
1. Association Between a History of breast cancer and Decreased Thyroid cancer-specific Mortality.
Lin S; Wang Z; Xing M
J Clin Endocrinol Metab; 2024 Apr; 109(5):1222-1230. PubMed ID: 38064679
[TBL] [Abstract] [Full Text] [Related]
2. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract] [Full Text] [Related]
3. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated cancers.
Jung M; Russell AJ; Liu B; George J; Liu PY; Liu T; DeFazio A; Bowtell DD; Oberthuer A; London WB; Fletcher JI; Haber M; Norris MD; Henderson MJ
Cancer Res; 2017 Feb; 77(4):971-981. PubMed ID: 27923830
[TBL] [Abstract] [Full Text] [Related]
4. An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer.
Morrow PK; Murthy RK; Ensor JD; Gordon GS; Margolin KA; Elias AD; Urba WJ; Weng DE; Rugo HS; Hortobagyi GN
Cancer; 2012 Sep; 118(17):4098-104. PubMed ID: 22281842
[TBL] [Abstract] [Full Text] [Related]
5. Increased frequency of the S-allele of the L-myc oncogene in breast cancer.
Isbir T; Yaylim I; Arîkan S; Küçücük S; Camlíca H
Mol Med; 2002 Sep; 8(9):521-4. PubMed ID: 12456990
[TBL] [Abstract] [Full Text] [Related]
6. L-MYC allelotype in renal cell carcinoma.
Presti JC; Hinckley J; Reuter VE
Cancer Genet Cytogenet; 1996 May; 88(1):66-8. PubMed ID: 8630982
[TBL] [Abstract] [Full Text] [Related]
7. Association of the SS genotype of the L-myc gene and loss of 18q sequences with a worse clinical prognosis in colorectal cancers.
Young J; Buttenshaw R; Butterworth L; Ward M; Searle J; Leggett B; Chenevix-Trench G
Oncogene; 1994 Apr; 9(4):1053-6. PubMed ID: 7907781
[TBL] [Abstract] [Full Text] [Related]
8. Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines.
Tyson FL; Boyer CM; Kaufman R; O'Briant K; Cram G; Crews JR; Soper JT; Daly L; Fowler WC; Haskill JS
Am J Obstet Gynecol; 1991 Sep; 165(3):640-6. PubMed ID: 1679963
[TBL] [Abstract] [Full Text] [Related]
9. Oncogene amplification in squamous cell carcinoma of the head and neck.
Merritt WD; Weissler MC; Turk BF; Gilmer TM
Arch Otolaryngol Head Neck Surg; 1990 Dec; 116(12):1394-8. PubMed ID: 2248738
[TBL] [Abstract] [Full Text] [Related]
10. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
Varley JM; Swallow JE; Brammar WJ; Whittaker JL; Walker RA
Oncogene; 1987; 1(4):423-30. PubMed ID: 3330785
[TBL] [Abstract] [Full Text] [Related]
